Treatment of Multifocal Lung Adenocarcinoma


About this study

To gather preliminary safety and outcome data for the multimodality treatment of lung adenocarcinoma in the setting of multifocal BAC.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  • Patient must be ≥ 18 years of age
  • Two or more GGO's or solid lesions suspicious for multifocal disease.
  • Clinical diagnosis of N0
  • No evidence of distant metastases
  • No prior intra-thoracic radiation therapy (NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted.), previous chemotherapy, or surgical resection for non-small cell lung cancer (NSCLC).
  • PFT's that show patient is capable of tolerating a lung resection.
  • Non-pregnant and non-lactating. Women of child-bearing potential must have a negative urine or serum pregnancy test to participate in the study.
  • Patient must be able to understand and willing to sign an IRB-approved informed consent document.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Dennis Wigle, M.D., Ph.D.

Closed for enrollment

Contact information:

Karlyn Pierson R.N., CCRP


More information


Publications are currently not available

Mayo Clinic Footer